Article in BioWorld: Adrenomed’s adrecizumab shows hints of efficacy in open-label COVID-19 study

28. August 2020

August 2020,
by Cormac Sheridan

Read the full article here.

CONTACT

Contact Info

  • +49 (0) 3302 20 77 8 0
  • +49 (0) 3302 20 77 8 15
  • info@adrenomed.com
  • ADRENOMED AG

Neuendorfstraße 15A 
Hennigsdorf b. Berlin 
D-16761, Germany.

Twitter
Linkedin

© 2017 Adrenomed AG | Imprint/Impressum | Legal Notice/Datenschutzerklärung